- The S&P 500 had a massive jump following news about coronavirus vaccine advancements.
- Bitcoin price initially followed the index but suffered an enormous rejection at $16,000.
Pfizer and Biontech announced a potential vaccine candidate against COVID-19 that seems to have a 90% effectiveness. The submission for Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA) will happen right after the required safety milestone is achieved. Dr. Albert Bourla, Pfizer Chairman and CEO, stated:
"Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19."
Right after the announcement, the S&P 500 and other indices jumped significantly, with Bitcoin following closely. However, the flagship cryptocurrency had a rejection at $16,000, breaking correlation.
Bitcoin price faces steep resistance at $16,000
After a massive 12% price spike on November 5 towards $15,750, Bitcoin started to slow down and finally saw a rejection at $15,960 on the next day. The flagship cryptocurrency has attempted to crack $16,000 again in the past 24 hours without successs.
BTC/USD 4-hour chart
So far, BTC price is down by 4% and seems to be pointing at the 50-SMA at $14,570 as an initial price target. The low at $14,344 established on November 7 can also become a potential key level, followed by $14,000, the 100-SMA.
BTC IOMAP chart
Despite the current selling pressure, the In/Out of the Money Around Price (IOMAP) chart shows stronger support than resistance. The support area between $14,869 and $15,313 with 534,000 BTC in volume greatly outweighs the resistance range at $15,332 - $16,240 with only 197,000 BTC.
Considering that a potential coronavirus vaccine might be ready and that the S&P 500 and other indices are turning bullish, a breakout above $16,000 could easily drive Bitcoin price towards $17,000.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.